Someone else's clock has started running against them: the company is being paid to solve a problem that is already cost
The model's full reasoning — Q4 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks whether management describes that its counterparts (customers, partners) are already losing something real and ongoing because they don't have what the company provides, and that this is visible in their behavior. The key is whether the dynamic is present: counterparty's clock is running, they incur costs until the company delivers, and they act accordingly. Looking through the transcript, management discusses various programs. For example, for ARO-APOC3 and ARO-ANG3, they plan to treat rare diseases like FCS, HoFH, etc. They mention staging commercial strategies. But do they describe that the patients or partners are currently losing something? The transcript is about a development-stage biotech. They talk about clinical trials, regulatory interactions, partnerships. The company sells royalties to Royalty Pharma for olpasiran. Are there any descriptions of counterparties already incurring losses due to lack of product? Possibly not. The question is about counterparts like customers or partners. The company has partnerships with Takeda, Amgen, etc. But the transcript doesn't describe those partners as losing money while waiting. The product candidates are in development, not launched. So there's no current loss being accrued by patients or payers because they can't get the drug yet. The company is working to get drugs to market but the drugs are not approved. So there's no running meter on the other side. The urgency is for the company to advance development, but it's not that partners are losing something now. The company mentions that Takeda is waiting for FDA feedback, but that's about regulatory process. No description of partners actively pressing for delivery because they are losing money. The question also mentions "meaningful relative to the company's current size" etc. This is likely a no. The transcript is about pipeline updates, financials, partnerships. No mention of counterparts incurring losses. Examples of running meter: none. The company monetized royalties, but that's about future. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
SYM · Q3 2022 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...YES The transcript shows management describing customers' ongoing pain from labor shortages and broken supply chains that prevent them from handling demand, with customers actively clamoring for faster deployments and wanting the system as quickly as possible.
CRL · Q2 2022 → YESThe question is whether management describes that their counterparties are already losing something real and ongoing — money, output, access, standing, time, or an opportunity — for as long as they do...
GTES · Q4 2021 → YESThe question is: Does management describe that ITS COUNTERPARTIES ARE ALREADY LOSING SOMETHING REAL AND ONGOING — money, output, access, standing, time, or an opportunity of their own — FOR AS LONG AS...